HK1214168A1 - 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途 - Google Patents

通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途

Info

Publication number
HK1214168A1
HK1214168A1 HK16102316.5A HK16102316A HK1214168A1 HK 1214168 A1 HK1214168 A1 HK 1214168A1 HK 16102316 A HK16102316 A HK 16102316A HK 1214168 A1 HK1214168 A1 HK 1214168A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
compositions
treatment
methods
blood glucose
Prior art date
Application number
HK16102316.5A
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Rodolphe Hajj
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of HK1214168A1 publication Critical patent/HK1214168A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
HK16102316.5A 2012-10-30 2016-02-29 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途 HK1214168A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720156P 2012-10-30 2012-10-30
EP12306354.7A EP2727587A1 (en) 2012-10-30 2012-10-30 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
PCT/EP2013/072728 WO2014068007A1 (en) 2012-10-30 2013-10-30 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Publications (1)

Publication Number Publication Date
HK1214168A1 true HK1214168A1 (zh) 2016-07-22

Family

ID=47143792

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102316.5A HK1214168A1 (zh) 2012-10-30 2016-02-29 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途

Country Status (17)

Country Link
US (2) US10092554B2 (zh)
EP (3) EP2727587A1 (zh)
JP (2) JP6387010B2 (zh)
KR (1) KR20150081323A (zh)
CN (2) CN110141663A (zh)
AU (2) AU2013340826B2 (zh)
BR (1) BR112015009702A2 (zh)
CA (1) CA2888576C (zh)
EA (1) EA031798B1 (zh)
ES (2) ES2757846T3 (zh)
HK (1) HK1214168A1 (zh)
IL (1) IL238283A0 (zh)
MX (1) MX2015005368A (zh)
NZ (1) NZ707139A (zh)
SG (2) SG10201801695XA (zh)
WO (1) WO2014068007A1 (zh)
ZA (1) ZA201503110B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2819664T1 (sl) * 2012-03-01 2017-12-29 Pharnext Novi sestavki za zdravljenje amiotrofične lateralne skleroze
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
WO2014156196A1 (ja) * 2013-03-29 2014-10-02 一般社団法人ファルマバレープロジェクト支援機構 ２型糖尿病治療剤
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CN105828815B (zh) 2013-12-17 2020-03-27 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
PL3485890T3 (pl) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
DK3125882T3 (da) 2014-04-01 2020-06-29 Boehringer Ingelheim Vetmedica Gmbh Behandling af metabolske lidelser i hestedyr
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
EP3197429A1 (en) * 2014-09-25 2017-08-02 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
CN104434952B (zh) * 2014-12-08 2017-10-24 成都恒瑞制药有限公司 一种治疗糖尿病的药物组合物及其制备方法
CN105055413A (zh) * 2015-07-23 2015-11-18 上海市第六人民医院 一种小檗碱和瑞格列奈的药物组合物
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor
US10220017B2 (en) 2015-08-27 2019-03-05 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
JP2022526842A (ja) * 2019-04-12 2022-05-26 エスディージー インコーポレイテッド 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法
EP4101448A4 (en) * 2020-02-07 2024-04-24 Neuroventi COMPOSITION CONTAINING A RILMENIDINE COMPOUND AS ACTIVE SUBSTANCE FOR THE TREATMENT OF FRAGILE X SYNDROME OR A RELATED DEVELOPMENTAL DISABILITY
CA3194581A1 (en) * 2020-10-01 2022-04-07 Alok Singh Bcg based vaccine compositions and methods of use thereof
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
CN114786683B (zh) 2021-04-09 2024-01-12 北京大学 一种siRNA、药物组合物以及使用其治疗糖尿病的方法
WO2022225984A1 (en) * 2021-04-19 2022-10-27 Spruce Health Sciences Inc. Nutritional supplement for regulating blood sugar

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2314719A1 (fr) * 1975-04-11 1977-01-14 Roussel Uclaf Nouveau medicament notamment diuretique
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
JP4821037B2 (ja) 2000-08-25 2011-11-24 富士通株式会社 ラマン増幅を用いた光増幅器およびラマン励起光源
SI1385548T1 (sl) * 2001-01-26 2007-10-31 Schering Corp Kombinacije zaviralca(-ev) absorpcije sterola s kardiovaskularnim(-i) sredstvom(-i) za zdravljenje vaskularnih obolenj
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
BR0307336A (pt) * 2002-01-30 2004-12-07 Pharmacia Corp Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas
AU2003251734A1 (en) * 2002-07-25 2004-02-16 Pharmacia Italia S.P.A. Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
US20070179181A1 (en) * 2004-03-17 2007-08-02 Baxter Andrew D Treatment of inflammatory disorders and pain using beta-aminoalcohols
CN101171002B (zh) * 2005-05-10 2011-07-13 实验室富尼耶公司 肝x受体激动剂的新用途
CA2609394A1 (en) * 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
GB2432526A (en) * 2005-11-24 2007-05-30 Arakis Ltd Use of ifenprodil for the treatment of ophthalmic diseases
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
EP1991211A1 (en) * 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
AR065669A1 (es) * 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihipertensivos para el tratamiento de hiperglucemia diabetica y las complicaciones diabeticas
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
JP2010536880A (ja) * 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
JP5685550B2 (ja) * 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US20140221286A1 (en) * 2011-09-21 2014-08-07 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
CA2879114A1 (en) * 2012-07-18 2014-01-23 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders

Also Published As

Publication number Publication date
CN104981240B (zh) 2019-03-15
US10092554B2 (en) 2018-10-09
EP3482753B1 (en) 2021-01-27
CA2888576A1 (en) 2014-05-08
SG11201503225UA (en) 2015-05-28
KR20150081323A (ko) 2015-07-13
US20150231123A1 (en) 2015-08-20
EP2914252A1 (en) 2015-09-09
EA201590849A1 (ru) 2015-11-30
EA031798B1 (ru) 2019-02-28
AU2018253580A1 (en) 2018-11-22
AU2018253580B2 (en) 2020-04-30
CN104981240A (zh) 2015-10-14
CN110141663A (zh) 2019-08-20
AU2013340826A1 (en) 2015-05-07
ZA201503110B (en) 2016-08-31
CA2888576C (en) 2021-02-16
JP2018188473A (ja) 2018-11-29
MX2015005368A (es) 2015-07-21
US10596160B2 (en) 2020-03-24
WO2014068007A1 (en) 2014-05-08
EP2727587A1 (en) 2014-05-07
SG10201801695XA (en) 2018-04-27
NZ707139A (en) 2019-01-25
ES2870028T3 (es) 2021-10-26
US20190008841A1 (en) 2019-01-10
EP2914252B1 (en) 2019-09-04
ES2757846T3 (es) 2020-04-30
BR112015009702A2 (pt) 2019-12-17
JP6387010B2 (ja) 2018-09-05
AU2013340826B2 (en) 2018-07-26
IL238283A0 (en) 2015-06-30
JP2016501841A (ja) 2016-01-21
EP3482753A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
HK1214168A1 (zh) 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途
IL244668A0 (en) Preparations and formulations for the prevention and treatment of diabetes and obesity, and methods for their production and use in the control of glucose and calories
ZA201403795B (en) Formulations for the treatment of diabetes
HK1198577A1 (zh) 型糖尿病的治療方案
EP2863910A4 (en) COMPOSITIONS AND METHOD FOR REGULATING GLUCOSE-HOMOSTOSTASE AND INSULIN EFFECT
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
HK1202458A1 (zh) 用於治療糖尿病的葡萄糖激酶活化劑組合物
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
IL228771A0 (en) Glycoside history and their use in the treatment of diabetes
HK1200367A1 (zh) 用於治療眼部疾病的 -孕甾烯- -三醇- -二酮衍生物
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HK1212253A1 (zh) 用於治療糖尿病的模式的組合
IL223289A0 (en) Treatment of type 2 diabetes
IL243845B (en) A preparation containing beta-casein a2 to regulate the blood glucose level
HK1223529A1 (zh) 針對患有糖尿病的人的低血糖治療
HK1207579A1 (zh) 用於預防或治療心臟疾病的組合物
ZA201408065B (en) Compositions and methods for the treatment of diabetes
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
SG11201501289TA (en) Preparation for preventing or treating type i diabetes
HK1196953A1 (zh) 用於治療糖尿病的製劑
GB201111126D0 (en) System for the self-monitoring and regulation of blood glucose
EP3035927A4 (en) Composition for treating ocular effects of diabetes
AU2010900296A0 (en) Method for regulating blood glucose levels
GB201104513D0 (en) Self-monitoring device for blood glucose regulation
TH127247B (th) องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง